HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,061,960 | +5.9% | 27,800 | 0.0% | 0.16% | +11.0% |
| Q2 2023 | $1,002,746 | -5.6% | 27,800 | 0.0% | 0.14% | -11.6% |
| Q1 2023 | $1,061,682 | -32.9% | 27,800 | 0.0% | 0.16% | -35.9% |
| Q4 2022 | $1,581,820 | +43.9% | 27,800 | 0.0% | 0.26% | +36.2% |
| Q3 2022 | $1,099,000 | -10.1% | 27,800 | 0.0% | 0.19% | -5.5% |
| Q2 2022 | $1,223,000 | +10.4% | 27,800 | 0.0% | 0.20% | +32.7% |
| Q1 2022 | $1,108,000 | -0.9% | 27,800 | 0.0% | 0.15% | +6.4% |
| Q4 2021 | $1,118,000 | -1.1% | 27,800 | 0.0% | 0.14% | -7.8% |
| Q3 2021 | $1,131,000 | -10.4% | 27,800 | 0.0% | 0.15% | -8.9% |
| Q2 2021 | $1,262,000 | +8.9% | 27,800 | 0.0% | 0.17% | +1.8% |
| Q1 2021 | $1,159,000 | -2.4% | 27,800 | 0.0% | 0.16% | -9.8% |
| Q4 2020 | $1,187,000 | +62.4% | 27,800 | 0.0% | 0.18% | +39.7% |
| Q3 2020 | $731,000 | -1.9% | 27,800 | 0.0% | 0.13% | -6.4% |
| Q2 2020 | $745,000 | +49.0% | 27,800 | 0.0% | 0.14% | +22.8% |
| Q1 2020 | $500,000 | +1.4% | 27,800 | 0.0% | 0.11% | +35.7% |
| Q4 2019 | $493,000 | +38.1% | 27,800 | +20.9% | 0.08% | +29.2% |
| Q3 2019 | $357,000 | -9.6% | 23,000 | 0.0% | 0.06% | -8.5% |
| Q2 2019 | $395,000 | +6.5% | 23,000 | 0.0% | 0.07% | +6.0% |
| Q1 2019 | $371,000 | +49.0% | 23,000 | +35.3% | 0.07% | +28.8% |
| Q4 2018 | $249,000 | -49.3% | 17,000 | -37.0% | 0.05% | -38.1% |
| Q3 2018 | $491,000 | -9.1% | 27,000 | -15.6% | 0.08% | -12.5% |
| Q2 2018 | $540,000 | -21.3% | 32,000 | -8.6% | 0.10% | -21.3% |
| Q1 2018 | $686,000 | -15.3% | 35,000 | -12.5% | 0.12% | -12.9% |
| Q4 2017 | $810,000 | -6.8% | 40,000 | -20.0% | 0.14% | -11.4% |
| Q3 2017 | $869,000 | -53.3% | 50,000 | -65.5% | 0.16% | -55.0% |
| Q2 2017 | $1,859,000 | -1.1% | 145,000 | 0.0% | 0.35% | -1.7% |
| Q1 2017 | $1,879,000 | +31.1% | 145,000 | 0.0% | 0.36% | +25.3% |
| Q4 2016 | $1,433,000 | -18.2% | 145,000 | 0.0% | 0.28% | -21.5% |
| Q3 2016 | $1,752,000 | +40.0% | 145,000 | 0.0% | 0.36% | +36.5% |
| Q2 2016 | $1,251,000 | -21.9% | 145,000 | 0.0% | 0.27% | -22.0% |
| Q1 2016 | $1,601,000 | -36.3% | 145,000 | 0.0% | 0.34% | -33.8% |
| Q4 2015 | $2,513,000 | +647.9% | 145,000 | +480.0% | 0.52% | +605.5% |
| Q3 2015 | $336,000 | – | 25,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |